Candidiasis Therapeutics Market Report 2026
Global Outlook – By Treatment Type (Medication, Supportive Therapy), By Anatomy Type (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis), By Mode Of Administration (Injectable, Oral, Other Mode Of Administrations), By Patient Population (Adults, Pediatrics), By End User (Hospitals, Specialty Clinics, Other End Users) - Market Size, Trends, Strategies, and Forecast to 2030
Candidiasis Therapeutics Market Overview
• Candidiasis Therapeutics market size has reached to $3.29 billion in 2025 • Expected to grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 4.3% • Growth Driver: Rising Clinical Trials Fueling Advancements In Candidiasis Therapeutics Market • Market Trend: Innovative Echinocandin Therapies Advancing Treatment Of Invasive Candida Infections • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Candidiasis Therapeutics Market?
Candidiasis is a fungal infection caused by the overgrowth of Candida species that naturally reside in the human body, particularly in the mouth, throat, gut, and genital area. Treatment for candidiasis typically involves antifungal medications, which can be topical (applied to the affected area) or oral (taken by mouth), depending on the severity and location of the infection. The main types of treatments in candidiasis therapeutics are medication, surgery and others. Medication refers to the use of pharmaceutical drugs or substances to treat, manage, or alleviate medical conditions. It includes various anatomy types, such as oral candidiasis, vulvovaginal candidiasis, cutaneous candidiasis, invasive candidiasis, and systemic candidiasis, and it includes a variety of modes of administration, including injectable, oral and others, it is used by adults and pediatrics by various end-users, such as hospitals, homecare, specialty clinics, and other end-users.
What Is The Candidiasis Therapeutics Market Size and Share 2026?
The candidiasis therapeutics market size has grown steadily in recent years. It will grow from $3.29 billion in 2025 to $3.4 billion in 2026 at a compound annual growth rate (CAGR) of 3.5%. The growth in the historic period can be attributed to increasing prevalence of immunocompromised patient populations, rising incidence of hospital-acquired fungal infections, widespread use of broad-spectrum antibiotics, availability of established antifungal drug classes, growth of hospital-based infectious disease care.What Is The Candidiasis Therapeutics Market Growth Forecast?
The candidiasis therapeutics market size is expected to see steady growth in the next few years. It will grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing research on novel antifungal drug classes, rising awareness of antifungal resistance management, expansion of outpatient antifungal treatment adoption, growing focus on pediatric candidiasis therapies, increasing investments in infectious disease drug development. Major trends in the forecast period include increasing development of targeted antifungal therapies, rising focus on early and accurate diagnosis, growing use of combination antifungal treatments, expansion of oral and systemic treatment options, enhanced monitoring of drug resistance patterns.
Global Candidiasis Therapeutics Market Segmentation
1) By Treatment Type: Medication, Supportive Therapy 2) By Anatomy Type: Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis 3) By Mode Of Administration: Injectable, Oral, Other Mode Of Administrations 4) By Patient Population: Adults, Pediatrics 5) By End User: Hospitals, Specialty Clinics, Other End Users Subsegments: 1) By Medication: Antifungal Drugs, Topical Treatments, Systemic Treatments 2) By Supportive Therapy: Probiotics, Symptom Management Therapies, Adjunct Nutritional SupportWhat Is The Driver Of The Candidiasis Therapeutics Market?
The increasing number of clinical trials is expected to propel the growth of the candidiasis therapeutics market going forward. Clinical trials are research studies conducted to evaluate the safety and effectiveness of new medical treatments, interventions, drugs, or devices in humans. Clinical trials play a pivotal role in the development of candidiasis therapeutics by providing a systematic and rigorous process to evaluate the safety and efficacy of potential treatments. For instance, in May 2023, according to ClinicalTrials.gov, a part of the National Institutes of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, in 2023, around 437,533 clinical trials were registered, compared to 399,499 registered studies in 2022 in all 50 states of the United States and across 221 countries. Therefore, the increasing number of clinical trials is driving the growth of the candidiasis therapeutics industry.Key Players In The Global Candidiasis Therapeutics Market
Major companies operating in the candidiasis therapeutics market are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Lupin Limited, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Cidara Therapeutics Inc., Amplyx Pharmaceuticals Inc., SCYNEXIS Inc., Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Candidiasis Therapeutics Market Trends and Insights
Major companies operating in the Candidiasis Therapeutics market are focusing on developing innovative solutions such as echinocandin antifungal therapy to improve treatment efficacy, reduce resistance, and enhance patient outcomes in managing invasive and systemic Candida infections. Echinocandin antifungal therapy is a class of drugs that inhibit β-(1,3)-D-glucan synthesis in fungal cell walls, effectively treating serious invasive Candida infections. For instance, in March 2023, Cidara Therapeutics Inc., a US-based biotech company partnered with Melinta Therapeutics, a US-based biopharmaceutical company, received U.S. FDA approval for REZZAYO (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is a novel once-weekly echinocandin antifungal, representing the first new treatment option for these infections in over a decade.What Are Latest Mergers And Acquisitions In The Candidiasis Therapeutics Market?
In May 2023, GSK plc, a UK-based pharmaceutical company, acquired Licensing rights for ibrexafungerp from Scynexism Inc. for $90 million. The acquisition provides GSK rights to develop and commercialize ibrexafungerp drugs, a first-in-class antifungal medication for treating vulvovaginal candidiasis (VVC), to accelerate the development and commercialization of ibrexafungerp. Scynexism Inc. is a US-based pharmaceutical company specializing in fungal disease therapies, including candidiasis.
Regional Outlook
North America was the largest region in the candidiasis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Candidiasis Therapeutics Market?
The candidiasis therapeutics market consists of revenues earned by entities by providing services such as medication services, diagnostic tests, consultation services, and medical monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The candidiasis therapeutics market also includes sales of topical creams and ointments, oral medications, medical devices, probiotics, nutritional supplements and antifungal medications that are used in providing these services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Candidiasis Therapeutics Market Report 2026?
The candidiasis therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the candidiasis therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Candidiasis Therapeutics Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $3.4 billion |
| Revenue Forecast In 2030 | $4.03 billion |
| Growth Rate | CAGR of 4.3% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Treatment Type, Anatomy Type, Mode Of Administration, Patient Population, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain |
| Key Companies Profiled | Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Lupin Limited, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Cidara Therapeutics Inc., Amplyx Pharmaceuticals Inc., SCYNEXIS Inc., Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |